ArticleJournal of the American Society of Nephrology : JASN2016
Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.
Article in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Perioperative Management of the Patient Receiving Maintenance Hemodialysis.Anesthesiology · 2025Article
- Contemporary Practice of Anemia Treatment Among Dialysis Patients in the United States.Kidney international reports · 2023Article
- Heart Failure in Patients with Chronic Kidney Disease.Journal of clinical medicine · 2023Review
- Hemodialysis Versus Peritoneal Dialysis Drug Expenditures: A Comparison Within the Private Insurance Market.Kidney medicine · 2023Article
- Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study.Kidney medicine · 2022Article
- Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial.BMC nephrology · 2021Article
- Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada.Kidney international reports · 2021Article
- Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013-2017.American journal of nephrology · 2021Article
- Dental caries status is associated with arteriosclerosis in patients on hemodialysis.Clinical and experimental nephrology · 2021Article
- Bundled Payment Reform and Dialysis Facility Closures in ESKD.Journal of the American Society of Nephrology : JASN · 2020Article
- Four years into MACRA: What has changed?Seminars in dialysis · 2020Article
- Calcimimetics and Bundled Reimbursement.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Article
- Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population.Journal of the American Society of Nephrology : JASN · 2019Article
- Possible link between dental diseases and arteriosclerosis in patients on hemodialysis.PloS one · 2019Article
- Jian-Pi-Yi-Shen Decoction Relieves Renal Anemia in 5/6 Nephrectomized Rats: Production of Erythropoietin via Hypoxia Inducible Factor Signaling.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Evaluating the Evidence behind Policy Mandates in US Dialysis Care.Journal of the American Society of Nephrology : JASN · 2018Article
- Perspective: Will We Ever Know the Optimal Hgb Level in ESRD?Journal of the American Society of Nephrology : JASN · 2018Article
- Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study.Canadian journal of kidney health and disease · 2018Article
- Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study.Clinical nephrology · 2017Article
- Treatment of renal anemia: Erythropoiesis stimulating agents and beyond.Kidney research and clinical practice · 2017Review
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia in patients with CKD, including those receiving dialysis, although clinical trials have identified risks associated with ESA use. We evaluated the effects of changes in dialysis payment policies and product labeling instituted in 2011 on mortality and major cardiovascular events across the United States dialysis population in an open cohort study of patients on dialysis from January 1, 2005, through December 31, 2012, with Medicare as primary payer. We compared observed rates of death and major cardiovascular events in 2011 and 2012 with expected rates calculated on the basis of rates in 2005-2010, accounting for differences in patient characteristics and influenza virulence. An abrupt decline in erythropoietin dosing and hemoglobin concentration began in late 2010. Observed rates of all-cause mortality, cardiovascular mortality, and myocardial infarction in 2011 and 2012 were consistent with expected rates. During 2012, observed rates of stroke, venous thromboembolic disease (VTE), and heart failure were lower than expected (absolute deviation from trend per 100 patient-years [95% confidence interval]: -0.24 [-0.08 to -0.37] for stroke, -2.43 [-1.35 to -3.70] for VTE, and -0.77 [-0.28 to -1.27] for heart failure), although non-ESA-related changes in practice and Medicare payment penalties for rehospitalization may have confounded the results. This initial evidence suggests that action taken to mitigate risks associated with ESA use and changes in payment policy did not result in a relative increase in death or major cardiovascular events and may reflect improvements in stroke, VTE, and heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.